Business
Press Release Sep 24 2020
Panacea Biotec Limited has informed the Exchange regarding a press release dated September 24, 2020, titled "Press Release - Successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll".
About this update from Panacea Biotec Limited
[{"type":"text","content":" Panacea Biotec Limited has informed the Exchange regarding a press release dated September 24, 2020, titled \"Press Release - Successful completion of Phase I/II study of its novel, Tetravalent recombinant chimeric Dengue candidate vaccine, DengiAll\". View Attachment","length":405,"tagName":"div"}]